Conferences  >  Medicine & Healthcare  >  Immunology and Allergic Diseases  >  Germany

Fraunhofer Institute for Cell Therapy and Immunology, University Hospital Leipzig

The Leipzig Immune ONcology (LION) Conference will bring together clinicians, scientists and industry to discuss latest developments and highlights on special issues of immune oncology. The annual meeting is organized by the Fraunhofer Institute for Cell Therapy and Immunology and the University Hospital Leipzig.

Fraunhofer Institute for Cell Therapy and Immunology, Jens Augustin;     Email: info@lion-conference.com

oncology, immunotherapy, gene therapy, cell therapy

Oncology,    Stem-cell Research & Therapy

Fraunhofer Institute for Cell Therapy and Immunology; Leipzig University Cancer Center (UCCL)

The Leipzig Immune ONcology (LION) Conference will bring together clinicians, scientists and industry to discuss latest developments and highlights on special issues of immune oncology. The annual meeting is organized by the Fraunhofer Institute for Cell Therapy and Immunology and the University Cancer Center of the University Hospital Leipzig.

Conference office: event lab. GmbH;     Phone: [+49 341 30 8884-72];     Email: info@lion-conference.com

cancer immuno therapy, immune oncolocgy

The European Association for Cancer Research (EACR)

The 6th edition of this conference will focus on cancer models that span in vitro investigations to in vivo cancer biology. It will emphasise how targeting the mechanisms that control tissue assembly – including the interactions with multiple epithelial cell types and the immune system – affects cancer progression and treatment response. Emerging topics also being discussed include mechanobiology, the immune response, how the extracellular matrix controls cell architecture, and how cell fate transitions underpin tissue morphogenesis and the metastatic cascade. The target audience for this conference is scientists, postdocs, and graduate students interested in the latest generation of engineered ex vivo models of tissue biology, in vivo cancer biology, and the use of these mechanobiological concepts for the development of cancer therapeutics. It will also be highly relevant for industry scientists interested in cutting-edge models of cancer and journal editors interested in ex vivo to in vivo models of biology and cancer.

Conference Officer Hannah Barrs;     Phone: [N/A];     Email: hannah.barrs@eacr.org

cancer research, oncology, in vitro models of cancer, ex vivo models of cancer, in vivo models of cancer, the extracellular matrix, cancer cell architecture, mechanobiology, immune response to cancer, tissue morphogenesis, the metastatic cascade, cancer immunotherapies, advanced imaging technologies, organoids, microtissue platforms, spatial transcriptomics, cell fate transitions, homeostasis, cancer progression, cancer therapeutic developments.

Oncology,    Molecular Biology

EMBL Heidelberg

The ability to grow tissues from stem cells in 3D culture to generate so-called organoids has revolutionised the study of tissue biology, especially human biology. This exciting technology has great potential for drug discovery and regenerative medicine. Because organoids model a variety of tissues with remarkably high fidelity, they allow for new discoveries in human development, homeostasis, regeneration, and disease. This symposium will bring together the leading researchers in this field, representing the premier conference for this research community, and providing a much-anticipated program that demonstrates how this field is truly pushing the boundaries for our understanding of tissue biology. This, the fifth edition of this established meeting will again bring together researchers from different fields to enhance our understanding of how organoids can be formed and maintained and their biomedical applications, from how they can be exploited to study disease to eventually use them to regenerate and replace human tissues. An aim for the 2025 edition of the symposium is the incorporation of more complementary technologies, such as multiomics, engineered embryo models and bioengineering as well as increased representation of the topic of cancer.

Inna Bösselmann;     Email: inna.boesselmann@embl.de